search button

Analysis of mutation of the c‑Kit gene and PDGFRA in gastrointestinal stromal tumors

  • Authors:
    • Chun‑Wei Xu
    • Shan Lin
    • Wu‑Long Wang
    • Wen‑Bin Gao
    • Jin‑Yan Lv
    • Jing‑Shan Gao
    • Li‑Ying Zhang
    • Yang Li
    • Lin Wang
    • Yu‑Ping Zhang
    • Yu‑Wang Tian

  • View Affiliations

  • Published online on: July 2, 2015     https://doi.org/10.3892/etm.2015.2613
  • Pages: 1045-1051
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to investigate mutation status of the c‑kit gene (KIT) and PDGFRA in patients with a gastrointestinal stromal tumor (GIST). In total, 93 patients with a GIST were included in the study, in which polymerase chain reaction amplification and gene sequencing were used to detect the sequences of exons 9, 11, 13 and 17 in KIT and exons 12 and 18 in PDGFRA. KIT mutations were detected in 64 cases (68.82%), of which exon 11 mutations were detected in 56 cases (60.22%), exon 13 mutations were detected in three cases (3.23%) and one case (1.08%) was shown to have a mutation in exon 17. The most common mutation in exon 11 was a deletion, which accounted for 55.36% (31/56) of the cases, followed by a point mutation observed in 26.79% (15/56) of the cases, while an insertion (tandem repeats) was identified in 14.29% (8/56) of the cases, and 3.57% (2/56) of the exon 11 mutations were deletions associated with a point mutation. The majority of the mutations were heterozygous, with only a few homozygous mutations. Mutational analysis revealed the mutations to be more concentrated in the classic hot zone at the 5'‑end, followed by the tandem repeat frame at the 3'‑end. In four cases, a mutation was detected in exon 18 of PDGFRA, of which one was associated with a mutation in KIT. The remaining three cases (10.34%, 3/29) were not associated with mutations in KIT and accounted for 37.5% (3/8) of the CD117‑negative GIST cases. Therefore, the majority of the GIST cases were characterized by mutations in KIT or PDGFRA, which were directly associated with the disease. Pairs of different mutations in the same exon of KIT, or KIT mutations coupled with pairs of mutations in PDGFRA, were detected in a small number of patients. Imatinib is a small molecule tyrosine kinase inhibitor and is the first line targeted treatment for GIST, resulting in markedly improved survival rates. Thus, gene mutation genotyping may provide inspiration and guidance for imatinib‑based targeted cancer therapy.
View Figures
View References

Related Articles

Journal Cover

September-2015
Volume 10 Issue 3

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.7
  • Ranked Medicine Research and Experimental
    (total number of cites)
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Xu CW, Lin S, Wang WL, Gao WB, Lv JY, Gao JS, Zhang LY, Li Y, Wang L, Zhang YP, Zhang YP, et al: Analysis of mutation of the c‑Kit gene and PDGFRA in gastrointestinal stromal tumors. Exp Ther Med 10: 1045-1051, 2015
APA
Xu, C., Lin, S., Wang, W., Gao, W., Lv, J., Gao, J. ... Tian, Y. (2015). Analysis of mutation of the c‑Kit gene and PDGFRA in gastrointestinal stromal tumors. Experimental and Therapeutic Medicine, 10, 1045-1051. https://doi.org/10.3892/etm.2015.2613
MLA
Xu, C., Lin, S., Wang, W., Gao, W., Lv, J., Gao, J., Zhang, L., Li, Y., Wang, L., Zhang, Y., Tian, Y."Analysis of mutation of the c‑Kit gene and PDGFRA in gastrointestinal stromal tumors". Experimental and Therapeutic Medicine 10.3 (2015): 1045-1051.
Chicago
Xu, C., Lin, S., Wang, W., Gao, W., Lv, J., Gao, J., Zhang, L., Li, Y., Wang, L., Zhang, Y., Tian, Y."Analysis of mutation of the c‑Kit gene and PDGFRA in gastrointestinal stromal tumors". Experimental and Therapeutic Medicine 10, no. 3 (2015): 1045-1051. https://doi.org/10.3892/etm.2015.2613